Phaseline

Companies › Verismo Therapeutics

Verismo Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SynKIR-110
Autologous T cells transduced with mesothelin-directed KIR-CAR
–Phase 1Ovarian CancerDec 2027
SynKIR-310
Autologous T cells transduced with CD19 KIR-CAR
–Phase 1B Cell LymphomaSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05568680SynKIR-110Phase 1Ovarian CancerOncologyDec 2027
NCT06544265SynKIR-310Phase 1B Cell LymphomaOncologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.